← Leaderboards
Marcelo Hill
Ardan Pharma S A S
$275,243
Attributed
$275,243
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $155K · FY2021–22$200K$150K$100K$50K$0
'21
'22
Funding mix
By agency
NIH$275,243 · 1
By mechanism
R21$275,243 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Anti-Pd-1”
- John Freymann · Leidos Biomedical Research, Inc.$5,261,900
- Tina Garyantes · Linnaeus Therapeutics, Llc$5,000,000
- Amaia Lujambio · Icahn School Of Medicine At Mount Sinai$4,251,878
- Alexander Huang · University Of Pennsylvania$3,639,634
- Yuliya Pylayeva-Gupta · Univ Of North Carolina Chapel Hill$3,602,417
- Jun Wang · New York University School Of Medicine$3,408,076
Research focus
Anti-Pd-1Anti-Pd1 AntibodiesAnti-Pd1 TherapyBaseBioinformaticsCancer ImmunotherapyCancer ModelCationsCd8-Positive T-LymphocytesCell Differentiation ProcessCellsClinical ResearchClinical Trials DesignCohortColonComplementCytokineDendritic CellsExhaustExhaustionFutureGeneticImmuneAnti-Ctla4